Search

Your search keyword '"Jokubaitis, V. G."' showing total 10 results
Start Over Author "Jokubaitis, V. G."
10 results on '"Jokubaitis, V. G."'

2. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Author

Spelman T., Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., Granella F., Lechner-Scott J., Sola P., Ferraro D., Grand'Maison F., Terzi M., Rozsa C., Boz C., Hupperts R., Van Pesch V., Oreja-Guevara C., van der Walt A., Jokubaitis V. G., Kalincik T., Butzkueven H., Luca G., UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Spelman T., Herring W.L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., Granella F., Lechner-Scott J., Sola P., Ferraro D., Grand'Maison F., Terzi M., Rozsa C., Boz C., Hupperts R., Van Pesch V., Oreja-Guevara C., van der Walt A., Jokubaitis V.G., Kalincik T., Butzkueven H., and Luca G.

Subjects
Pharmacology, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Fingolimod Hydrochloride, Cost-Benefit Analysis, Natalizumab, Health Policy, Public Health, Environmental and Occupational Health, Humans, multiple sclerosis, effectiveness, cost, natalizumab, fingolimod, Immunosuppressive Agents
Abstract

Background: Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies, glatiramer acetate, dimethyl fumarate, and teriflunomide, known collectively as “BRACETD”) often switch to natalizumab or fingolimod. Objective: The aim was to estimate the comparative effectiveness of switching to natalizumab or fingolimod or within BRACETD using real-world data and to evaluate the cost-effectiveness of switching to natalizumab versus fingolimod using a United Kingdom (UK) third-party payer perspective. Methods: Real-world data were obtained from MSBase for patients relapsing on BRACETD in the year before switching to natalizumab or fingolimod or within BRACETD. Three-way-multinomial-propensity-score–matched cohorts were identified, and comparisons between treatment groups were conducted for annualised relapse rate (ARR) and 6-month–confirmed disability worsening (CDW6M) and improvement (CDI6M). Results were applied in a cost-effectiveness model over a lifetime horizon using a published Markov structure with health states based on the Expanded Disability Status Scale. Other model parameters were obtained from the UK MS Survey 2015, published literature, and publicly available UK sources. Results: The MSBase analysis found a significant reduction in ARR (rate ratio [RR]=0.64; 95% confidence interval [CI] 0.57–0.72; p&nbsp

Published
2021

3. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study

Author

Mahurkar, S, Moldovan, M, Suppiah, V, Sorosina, M, Clarelli, F, Liberatore, G, Malhotra, S, Montalban, X, Antigüedad, A, Krupa, M, Jokubaitis, V G, McKay, F C, Gatt, P N, Fabis-Pedrini, M J, Martinelli, V, Comi, G, Lechner-Scott, J, Kermode, A G, Slee, M, Taylor, B V, Vandenbroeck, K, Comabella, M, Boneschi, F M, Australian, The, and King, C

Published
2016
Full Text
View/download PDF

4. The MSBase pregnancy, neonatal outcomes, and women’s health registry

Author

Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Jokubaitis, V. G.; Skibina, O.; Alroughani, R.; Butzkueven, H.; Eichau, S.; Fragoso, Y.; Hellwig, K.; Hughes, S. E.; Rath, L.; van der Walt, A.; Gray, O., School of Medicine, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Jokubaitis, V. G.; Skibina, O.; Alroughani, R.; Butzkueven, H.; Eichau, S.; Fragoso, Y.; Hellwig, K.; Hughes, S. E.; Rath, L.; van der Walt, A.; Gray, O., and School of Medicine

Abstract

Background: family planning and pregnancy decisions are key considerations in the management of women with multiple sclerosis (MS), who are typically diagnosed between the ages of 20–40 years. Despite a strong evidence base that pregnancy is not harmful for women with MS, many knowledge gaps remain. These include: best management strategies through pregnancy in the era of highly effective disease-modifying therapies (DMT); foetal risks associated with DMT exposure in utero or in relation to breastfeeding; knowledge base around the use of assisted reproductive technologies; the long-term impact of pregnancy on disease outcomes, as well as the impact of long-term DMT use on women’s health and cancer risk. Methods: here, we describe the new MSBase pregnancy, neonatal outcomes and women’s health registry. We provide the rationale for, and detailed description of, the variables collected within the registry, together with data acquisition details. Conclusion: the present paper will act as a reference document for future studies., National Health and Medical Research Council of Australia; MSBase Foundation; Roche; Merck; Biogen; Novartis; Bayer-Schering; Sanofi Genzyme; Teva

Published
2021

5. 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

Author

Jokubaitis, V. G., Spelman, T., Kalincik, T., Travaglini, D., Paolicelli, D., Duquette, P., Verheul, F., and Ondokuz Mayıs Üniversitesi

Abstract

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- OCT 07-10, 2015 -- Barcelona, SPAIN Lugaresi, Alessandra/0000-0003-2902-5589; Horakova, Dana/0000-0003-1915-0036; McCombe, Pamela/0000-0003-2704-8517; Havrdova, Eva Kubala/0000-0002-9543-4359 WOS: 000365729400172 … European Comm Treatment & Res Multiple Sclerosis

Published
2015

7. 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

Author

Jokubaitis, V. G., Spelman, T., Kalincik, T., Travaglini, D., Paolicelli, D., Duquette, P., Girard, M., Prat, A., Havrdova, E., Horakova, D., Izquierdo, G., Grammond, P., Pucci, E., Grand Maison, F., Bergamaschi, R., Granella, F., Pesch, V., Hupperts, R., Iuliano, G., Spitaleri, D., Sola, P., Boz, C., Fernandez-Bolanos, R., Petersen, T., Verheul, F., Olascoaga, J., Pamela Ann McCombe, Rozsa, C., Lechner-Scott, J., Terzi, M., Hodgkinson, S., Ramo, C., Saladino, M. L., Butzkueven, H., Lugaresi, A., Trojano, M., and MSBase Study Grp

8. Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

Author

Jokubaitis, V. G., Havrdova, E., Horakova, D., Izquierdo, G., Kalincik, T., Walt, A., Nguyen, A. -L, Terzi, M., Alroughani, R., Duquette, P., Girard, M., Prat, A., Boz, C., Sola, P., Lugaresi, A., Lechner-Scott, J., Barnett, M., Grand Maison, F., Grammond, P., Ramo, C., Turkoglu, R., Mccombe, P., Hupperts, R., Bolanos, R. Fernandez, Pucci, E., Trojano, M., Granella, F., Spitaleri, D., Pesch, V., Soysal, A., Eva Kubala Havrdova, Verheul, F., Vucic, S., Hodgkinson, S., Slee, M., Ampapa, R., Prevost, J., Menoyo, J. L. Sanchez, Skibina, O., Iuliano, G., Solaro, C., Olascoaga, J., Shaw, C., Madsen, K., Naidoo, K., Hyde, R., and Butzkueven, H.

9. The MSBase pregnancy, neonatal outcomes, and women’s health registry

Author

Anneke van der Walt, Kerstin Hellwig, Ayse Altintas, Sara Eichau, Olga Skibina, Vilija Jokubaitis, Orla Gray, Helmut Butzkueven, Louise Rath, Raed Alroughani, Yara Dadalti Fragoso, Stella Hughes, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Jokubaitis, V. G., Skibina, O., Alroughani, R., Butzkueven, H., Eichau, S., Fragoso, Y., Hellwig, K., Hughes, S. E., Rath, L., van der Walt, A., Gray, O., and School of Medicine

Subjects
Registry, medicine.medical_specialty, Multiple Sclerosis, Women’s Health, MSBase, lcsh:RC346-429, Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, medicine, Neurosciences, Neurology, lcsh:Neurology. Diseases of the nervous system, Pharmacology, 030219 obstetrics & reproductive medicine, business.industry, Multiple sclerosis, Neonatal outcomes, Women’s health, medicine.disease, Clinical neurology, Family planning, Family medicine, Neonatal Outcomes, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

Background: family planning and pregnancy decisions are key considerations in the management of women with multiple sclerosis (MS), who are typically diagnosed between the ages of 20–40 years. Despite a strong evidence base that pregnancy is not harmful for women with MS, many knowledge gaps remain. These include: best management strategies through pregnancy in the era of highly effective disease-modifying therapies (DMT); foetal risks associated with DMT exposure in utero or in relation to breastfeeding; knowledge base around the use of assisted reproductive technologies; the long-term impact of pregnancy on disease outcomes, as well as the impact of long-term DMT use on women’s health and cancer risk. Methods: here, we describe the new MSBase pregnancy, neonatal outcomes and women’s health registry. We provide the rationale for, and detailed description of, the variables collected within the registry, together with data acquisition details. Conclusion: the present paper will act as a reference document for future studies., National Health and Medical Research Council of Australia; MSBase Foundation; Roche; Merck; Biogen; Novartis; Bayer-Schering; Sanofi Genzyme; Teva

Published
2021

10. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Author

Spelman T, Herring WL, Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, van Pesch V, Van Wijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Triviño, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, and Butzkueven H

Subjects
Humans, Natalizumab therapeutic use, Fingolimod Hydrochloride therapeutic use, Immunosuppressive Agents therapeutic use, Cost-Effectiveness Analysis, Cost-Benefit Analysis, State Medicine, United Kingdom, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis drug therapy
Abstract

Aim: To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis (RES-RRMS)., Methods: Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD). Matched cohorts were selected by 3-way multinomial propensity score matching, and the annualized relapse rate (ARR) and 6-month-confirmed disability worsening (CDW6M) and improvement (CDI6M) were compared between treatment groups. Comparative effectiveness results were used in a cost-effectiveness model comparing natalizumab and fingolimod, using an established Markov structure over a lifetime horizon with health states based on the Expanded Disability Status Scale. Additional model data sources included the UK MS Survey 2015, published literature, and publicly available sources., Results: In the comparative effectiveness analysis, we found a significantly lower ARR for patients starting natalizumab compared with fingolimod (rate ratio [RR] = 0.65; 95% confidence interval [CI], 0.57-0.73) or BRACETD (RR = 0.46; 95% CI, 0.42-0.53). Similarly, CDI6M was higher for patients starting natalizumab compared with fingolimod (hazard ratio [HR] = 1.25; 95% CI, 1.01-1.55) and BRACETD (HR = 1.46; 95% CI, 1.16-1.85). In patients starting fingolimod, we found a lower ARR (RR = 0.72; 95% CI, 0.65-0.80) compared with starting BRACETD, but no difference in CDI6M (HR = 1.17; 95% CI, 0.91-1.50). Differences in CDW6M were not found between the treatment groups. In the base-case cost-effectiveness analysis, natalizumab dominated fingolimod (0.302 higher quality-adjusted life-years [QALYs] and £17,141 lower predicted lifetime costs). Similar cost-effectiveness results were observed across sensitivity analyses., Conclusions: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results